Rocket Lab Q4 FY12/23 Earnings Review

Rocket Lab Q4 FY12/23 Earnings Review
Photo by Andy Holmes / Unsplash

A VC play with a tradable ticker.

DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis in this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Cestrian Capital Research, Inc., its employees, agents or affiliates, including the author of this note, or related persons, may have a position in any stocks, security, or financial instrument referenced in this note. Any opinions, analyses, or probabilities expressed in this note are those of the author as of the note's date of publication and are subject to change without notice. Companies referenced in this note or their employees or affiliates may be customers of Cestrian Capital Research, Inc. Cestrian Capital Research, Inc. values both its independence and transparency and does not believe that this presents a material potential conflict of interest or impacts the content of its research or publications.

Stardust or Supernova, Time Will Tell

by Alex King

RocketLab ($RKLB) is not, on the face of it, a very good business. It consumes cash like it is going out of fashion and has no currently visible path to cash generation. Growth rates have been falling as has backlog. And the stock is languishing in the $4-8/share range, has been for the last two years nearly, way below the $10/share price at which owners of the prior holding company were able to sell when the stock listed in a SPAC process.

So, why bother owning this thing? Indeed, why would we include it as a member of our Inner Circle Defense Model Portfolio?

I’ll explain my own logic below - you can decide whether this is a good idea for you or not!